PFIZER INC Proceeds from Sale of Equity Method Investments
PFIZER INC (PFE) reported Proceeds from Sale of Equity Method Investments of $0 for the 3-month period ending 2026-03-29, per its 10-Q filed 2026-05-05.
Financial Statements › Cash Flow › Investing Activities
us-gaap:ProceedsFromSaleOfEquityMethodInvestments · last filed 2026-05-05
- PFIZER INC proceeds from sale of equity method investments for the quarter ending 2026-03-29 was $0.00, a 100.00% decline year-over-year.
- PFIZER INC proceeds from sale of equity method investments for the quarter ending 2025-12-31 was $0.00, a 100.00% decline year-over-year.
- PFIZER INC proceeds from sale of equity method investments for the quarter ending 2025-09-28 was $0.00.
- PFIZER INC proceeds from sale of equity method investments for the quarter ending 2025-06-29 was $0.00.
- PFIZER INC proceeds from sale of equity method investments for fiscal 2025 was $6.31B, a 10.36% decline from fiscal 2024.
- PFIZER INC proceeds from sale of equity method investments for fiscal 2024 was $7.04B.
- PFIZER INC proceeds from sale of equity method investments for fiscal 2023 was $0.00.
- PFIZER INC proceeds from sale of equity method investments for fiscal 2022 was $0.00.
| Period end | Proceeds from Sale of Equity Method Investments 3 month | Proceeds from Sale of Equity Method Investments 6 month | Proceeds from Sale of Equity Method Investments 9 month | Proceeds from Sale of Equity Method Investments 12 month |
|---|---|---|---|---|
| 2026-03-29 | $0.00 10-Q · filed 2026-05-05 | $0.00 derived: sum of 2 quarters · filed 2026-05-05 | $0.00 derived: sum of 3 quarters · filed 2026-05-05 | $0.00 derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $6.31B 10-K · filed 2026-02-26 |
| 2025-09-28 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $6.31B 10-Q · filed 2025-11-04 | $9.86B derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-06-29 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $6.31B 10-Q · filed 2025-08-05 | $9.86B derived: sum of 3 quarters · filed 2026-05-05 | $9.86B derived: sum of 4 quarters · filed 2026-05-05 |
| 2025-03-30 | $6.31B 10-Q · filed 2026-05-05 | $9.86B derived: sum of 2 quarters · filed 2026-05-05 | $9.86B derived: sum of 3 quarters · filed 2026-05-05 | $9.86B derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $3.55B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $3.55B derived: sum of 2 quarters · filed 2026-02-26 | $3.55B derived: sum of 3 quarters · filed 2026-02-26 | $7.04B 10-K · filed 2026-02-26 |
| 2024-09-29 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $0.00 derived: sum of 2 quarters · filed 2025-11-04 | $3.49B 10-Q · filed 2025-11-04 | $3.49B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-05 | $3.49B 10-Q · filed 2025-08-05 | $3.49B derived: sum of 3 quarters · filed 2026-02-26 | $3.49B derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $3.49B 10-Q · filed 2025-05-05 | $3.49B derived: sum of 2 quarters · filed 2026-02-26 | $3.49B derived: sum of 3 quarters · filed 2026-02-26 | $3.49B derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $0.00 derived: sum of 2 quarters · filed 2026-02-26 | $0.00 derived: sum of 3 quarters · filed 2026-02-26 | $0.00 10-K · filed 2026-02-26 |
| 2023-10-01 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $0.00 derived: sum of 2 quarters · filed 2024-11-04 | $0.00 10-Q · filed 2024-11-04 | |
| 2023-07-02 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-05 | $0.00 10-Q · filed 2024-08-05 | ||
| 2023-04-02 | $0.00 10-Q · filed 2024-05-08 | |||
| 2022-12-31 | $0.00 10-K · filed 2025-02-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |